Beyond Micronization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Beyond Micronization
Emerging methods could provide alternative ways of producing inhalable drug particles.


Pharmaceutical Technology
Volume 35, Issue 5, pp. 52-54

Supercritical-fluid technology

Supercritical-fluid technology, a more established method than PRINT, may soon be used to manufacture an FDA-approved drug. MAP Pharmaceuticals has been producing Levadex, its orally inhaled migraine therapy, through supercritical-fluid crystallization. The company completed clinical development for the drug last year and will submit a New Drug Application during the first half of 2011, according to the Form 10-K filed on Mar. 4, 2011.

Supercritical-fluid technology has been around for more than a century, and it is a common method for making decaffeinated coffee. In the mid 1990s, the pharmaceutical industry began examining the technique as a way of manufacturing drug particles. Because the process is rapid, and because no solvent is present during crystallization, drugmakers thought that supercritical-fluid technology could yield uniform particles.

Supercritical fluids could be considered a fourth state of matter that combines the properties of liquids and gases. These fluids can act as solvents or antisolvents. Carbon dioxide becomes a supercritical fluid when it is heated above 31.1 C and held at a pressure higher than 73.8 bar. Because of these characteristics, carbon dioxide has become the most common supercritical fluid in the pharmaceutical industry.

Supercritical antisolvent precipitation (SAS) is one way to produce inhalable drug particles. In this method, a solution of drug and organic solvent (e.g., budesonide in ethanol) is introduced into a flow of supercritical carbon dioxide, which extracts the solvent rapidly from the drug solution. The drug substance then becomes supersaturated and forms particles in milliseconds. Variations in SAS processes are distinguished by the ways in which the drug solution and supercritical fluid interact. Some SAS processes are more efficient than others, but each of them yields dry powders in a single step.

Because carbon dioxide's critical temperature is not much different from ambient conditions, SAS is an attractive method for processing pharmaceuticals, says Peter York, chief scientist at CrystecPharma and emeritus professor of physical pharmaceutics at the University of Bradford, United Kingdom. The process yields dry powders without additives or residual solvents that might be unacceptable to regulators.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here